Accrol Group Holdings plc is a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues and AFH products to supply retailers throughout the UK. Accrol imports parent reels from around the world and converts them into finished goods at the Company’s 350,000 sq. ft. manufacturing, storage and distribution facility in Blackburn, Lancashire. Accrol currently manufactures approximately 17 million units per week and supplies some of the UK’s largest retailers.

Accrol Group Holdings plc is listed on AIM, the growth market of the London Stock Exchange.

The Company was incorporated and registered in England and Wales on 30 April 2014 under the Act with registered number 9019496 as a private company limited by shares with the name Aghoco 1220 Limited. The name of the Company was changed to Accrol Group Holdings Limited on 1 August 2014. The Company was re-registered as a public limited company with the name Accrol Group Holdings plc on 1st June 2016. Accrol Group Holdings plc’s main country of operation is the UK.

The Company, and the Group, trade under the name “Accrol Papers”.

Accrol currently has four warehouses providing 3,500 tonnes of storage for finished goods, allowing
for at least two weeks supply, a key criteria for certain Multiples.

11 July 2016



Accrol Group Holdings plc (the "Company" or "Accrol")

Deferred Share Buyback



Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces completion of the buyback of deferred shares in the Company.

The Company has bought back 27,476,142 deferred shares of £0.001 each (the "Deferred Shares") held by shareholders of the Company on the share register as at 1 June 2016, for total consideration of £1 (the "Share Buyback"), further details of which can be found in the Company's AIM admission document dated 2 June 2016.

Following the Share Buyback there will be no Deferred Shares in issue and the issued share capital of the Company will consist of 93,012,002 ordinary shares of £0.001 each.

ST in this weeks IC - Analysts predictions that revenues will grow by 15% to £138m in the financial year to end April 2017 to produce a near 10% hike in cash profit to £16.4m and deliver pre-tax profit of £13.4m. On that basis ,expect EPS of 10.7p and a dividend per share of 6p.I fully expect the board to reiterate current year guidance, especially as likely weaker UK economic conditions after the EU referendum is great news for the company.

On Monday, Accrol Group Holdings PLC (ACRL:LSE) closed at 117.00, 0.01% below its 52-week high of 116.99, set on Jun 10, 2016.


Just need the whole country to go down with the sh-ts. :-))

Full year results for the year ended 30 April 2016

RNS


RNS Number : 9182E

Accrol Group Holdings PLC

22 July 2016




22 July 2016



Accrol Group Holdings plc (the "Company" or "Accrol")

Audited full year results for the year ended 30 April 2016

Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces its audited results for the financial year ended 30 April 2016.

Financial Highlights1

· Revenue increased 17% to £118m (2015: £101m)

· Adjusted Gross Margin increased 2.1% to 28.1% (2015: 26.0%)

· Adjusted EBITDA of £15.0m, up 22% (2015: £12.3m)

· Continued strong cash generation year-on-year

· Net debt reduced by £1.1m

· Successful IPO on London Stock Exchange's AIM market on 10 June 2016

Operational Highlights1

· 35% market share of the Discount sector (Discounters accounting for 69% of revenues, up 6% on 2015) after contract wins during the year

· 15% increase in sales to Multiples

· Focus on Private Label products which are taking market share from Brands

· Continued investment in machinery with £3.2m invested in two high-speed converting lines

· Capacity increased to 118,000 tonnes with a further 25,000 tonnes to be added

· UK exclusivity secured for a new luxury tissue, NTT (New Textured Tissue)

Commenting on the results, Steve Crossley, Accrol's newly appointed CEO said:



"I am delighted to report a strong first set of results following our listing on AIM in June. FY16 has been a very successful year for Accrol and our focus on supplying Private Label products to both Discounters and Multiples has generated 17% revenue growth. We have continued to invest in new capacity as we ready the business for the next stage of our strategic plan. The current year has started encouragingly and we remain confident in the outlook for FY17."



The Company's annual report for the year ended 30 April 2016 (including notice of the annual general meeting to be held at Stanley House Hotel, Mellor, Lancashire, BB2 7NP on 30 September 2016 at 11am) (the "annual report") will shortly be available for downloading from the Company's web site at http://www.accrol.co.uk/investor-relations/.



Notes: (1) 2015 numbers based on unaudited proforma for 12 months ended 30 April 2015.

-------------------------------------------------------------------------------------------



Friday 22 July 2016 1:26pm




Woof: Discount loo roll company targets top dog Andrex after Brexit boost





William Turvill

I write about mergers and acquisitions (M&A), deals and investment for City A.M. [..] Show more


A discount loo roll company which took a punt on floating shortly before the EU referendum believes Brexit provides an opportunity to target the big dogs of the industry. Namely, Andrex.

The Northern company today reported its first results since its initial public offering (IPO) on the alternative investment market (Aim).



Revenue increased by 17 per cent to £118m in the year to 30 April, with adjusted earnings before interest, taxation, depreciation and amortisation (Ebitda) of £15m – up 22 per cent.


Accrol’s decision to float in June stood out at a time when many other firms were understood to be holding back from making IPO decisions amid referendum uncertainty. After the Brexit vote, a number of IPOs have been cancelled or postponed.

But Accrol has no regrets.

Chief executive Steve Crossley told City A.M.: “I think in hindsight it’s been very good timing for us. There were a lot of comments in the marketplace at the time, around ‘are you you sure you should not be waiting?’” But he added that the “the timing has proved to be nothing but very good”.

The company also believes the Brexit vote, and the chances of a recession, presents it with an opportunity.

“As I cast my mind back to 2008, the real winners… were the discounters,” said Accrol’s chief financial officer James Flude.

“We are the leading player in that [discount] sector, it is a sector that it growing at 10 per cent per annum. We’re primarily supplying private labels… which is taking share from brands. We’re well positioned to take advantage of some of those changes.”


Asked what brands Accrol can challenge, Flude said: “As we understand it, and from reading the trade press, Andrex is the market leader – which is about… a quarter of the market – is declining at something like eight per cent per annum.

“And there was an article in Tissue World a couple of issues ago where the UK marketing manager talked about Andrex and its decline. And if you read between the lines, they were basically saying that it’s difficult to sell products when they’re not on promotion.”

He believes Accrol’s tissue products offer better value for money than pricier rivals, adding: “You touch and you feel it, there’s not a lot of difference in the product, but there’s a 30-35 per cent difference in the price.”

ST in IC today - on a forward PE ratio of 10, and offering a prospective dividend yield of 5%, buy.

it doesn't move a lot and nor is there any volume

patience. :-))

Seems a large spread price today? When a stock has a low trading volume, it is considered illiquid because it is not easily converted to cash. As a result, a broker will require more compensation for handling the transaction, accounting for the larger spread

IC - As IC's Simon Thompson flagged in June, it's always worth asking why family owners of a profitable company decide to sell part of their holdings, but the listing allowed the Hussains and their private equity fund backer Northedge , to pay down debts after a period of expansion.
Despite the strengthened balance sheet, the company remains lowly valued on 11 times earnings for the year to April 2017, has a punchy dividend yield and is well established in a largely unchanging sector. Little wonder that the Hussain family has kept some skin in the game.

Seems to be a seller in 25,000 lots. Good rise today.

2nd September 2016



Accrol Group Holdings plc (the "Company" or "Accrol")

New manufacturing facility in Leyland, Lancashire to support the Company's growth plans



Accrol Group Holdings plc, the AIM listed leading independent tissue converter, is pleased to announce that it has reached an agreement with Lancashire County Developments (Property) Ltd (the economic development arm of Lancashire County Council) to lease a new 168,000 sq. ft. facility in Leyland, Lancashire. The new facility will support the Company's continued growth with both the Discounters and the Major Multiples in the UK.

The new property will initially house two high speed tissue converting lines purchased by Accrol in April 2016 and also provide finished goods warehousing space, with potential to add two further converting lines if required.

Installation and commissioning of the first two lines will take place during late 2016, with manufacturing planned to start in January 2017. The project is expected to create around 80 new jobs.

Commenting on the new facilities, Steve Crossley, Accrol's CEO said:



"This additional capacity underlines our strategy of investment ahead of growth in state-of-the-art machinery and facilities. It will position Accrol to benefit from underlying organic growth in the Discount sector and enable further growth with the Major Multiples. At the same time, we will focus on improving efficiency at the existing Blackburn sites to further increase our total capacity

Large buys today.

Large buys today.

Forecast Key Dates

Next AGM Confirmed 30/09/2016
Next year end (to be reported) 30/04/2017
Next prelim announcement Approximate 24/07/2017
Next annual report due Approximate 04/09/2017
Next interim announcement Approximate 25/12/2017

New high.:-))

And in my opinion with plenty more to go, can't call it but even at this level will be a multi-bagger.

Was hoping it would fall to stock up on more and if it does I most certainly will

All good for me glad I got in at the IPO should have got more then, but then isn't that always the way when you have a good one

Good to hear from you Stevesham. I'm up 16% now. :-)) This will move with the installation of the new machine/ machines and any announcements at the agm.

Hi Dreamcatcher love your posts, and yes this is a good solid one for pure growth I so need to buy more when prudent to do so

16% for me too, which if I am right is only the tip of the iceberg

I think if it drops below £1.20 I could be quite easily tempted to get more, however I really can only see this going one way and that is up!

Bought more today Stevesham, sitting on a good holding now.